An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice

Percentage of Participants Receiving Tocilizumab Monotherapy Who Discontinued Unspecified Conventional Synthetic Disease-modifying Antirheumatic Drugs (csDMARDs)

The percentage of participants who discontinued treatment with unspecified csDMARDs prior to being assigned to tocilizumab monotherapy is presented by reason for discontinuation.

Time frame: Day 1 (assessment of discontinuations within prior 2 years)

Mean Number of Tocilizumab Infusions Over the Study Period

Time frame: Up to 30 months

Percentage of Participants Who Received Tocilizumab Infusions Over the Study Period

The percentage of participants who received infusions is presented by category of total infusions received over the study period.

Time frame: Up to 13.4 months

Percentage of Participants With No Modification of Tocilizumab Treatment Over the Study Period

The percentage of participants with no modifications (dose modification or discontinuation) is presented.

Time frame: Up to 30 months

Percentage of Participants With at Least One csDMARD Intensification During the Study

csDMARD intensification was defined as an addition of a csDMARD without suppression of other csDMARD, dose increase of a csDMARD, switch (addition and suppression) of a csDMARD without intolerance, biological abnormality or symptom improvement to the suppressed csDMARD, or modification of the MTX administration route (from oral route to intramuscular/subcutaneous) with dose increase or maintenance.

Time frame: Up to 30 months

Percentage of Participants in Disease Activity Score Based on 28-joint Count and Erythrocyte Sedimentation Rate (DAS28-ESR) Low Disease Activity (LDA) at Month 12

DAS28-ESR was calculated from the number of swollen joints and tender joints using the 28-joint count, ESR (mm/hour) and patient's global assessment of disease activity; scores range from 0 to 10, where lower scores indicate less disease activity. A score of ≤3.2 was considered to be DAS28-ESR LDA. Participants with missing data were considered to have failed to achieve the outcome.

Time frame: Month 12

Percentage of Participants With DAS28-ESR Remission at Month 12

DAS28-ESR was calculated from the number of swollen joints and tender joints using the 28-joint count, ESR (mm/hour) and patient's global assessment of disease activity; scores range from 0 to 10, where lower scores indicate less disease activity. A score of \<2.6 was considered to be DAS28-ESR remission. Participants with missing data were considered to have failed to achieve the outcome.

Time frame: Month 12

Percentage of Participants With Clinical Disease Activity Index (CDAI) LDA at Month 12

CDAI was calculated from the number of swollen joints and tender joints using the 28-joint count and the patient's global assessment of disease activity and physician's global assessment of disease activity; CDAI scores range from 0 to 76, where lower scores indicate less disease activity. A score of ≤10 was considered to be CDAI LDA. Participants with missing data were considered to have failed to achieve the outcome.

Time frame: Month 12

Percentage of Participants With CDAI Remission at Month 12

CDAI was calculated from the number of swollen joints and tender joints using the 28-joint count and the patient's global assessment of disease activity and physician's global assessment of disease activity; CDAI scores range from 0 to 76, where lower scores indicate less disease activity. A score of ≤2.8 was considered to be CDAI remission. Participants with missing data were considered to have failed to achieve the outcome.

Time frame: Month 12

Percentage of Participants With Simplified Disease Activity Index (SDAI) LDA at Month 12

SDAI was calculated from the number of swollen joints and tender joints using the 28-joint count, C-reactive protein (CRP) (milligrams per liter (mg/L)) per , and the patient's global assessment of disease activity and physician's global assessment of disease activity; SDAI scores range from 0 to 86, where lower scores indicate less disease activity. A score of ≤11 was considered to be SDAI LDA. Participants with missing data were considered to have failed to achieve the outcome.

Time frame: Month 12

Percentage of Participants With SDAI Remission at Month 12

SDAI was calculated from the number of swollen joints and tender joints using the 28-joint count, CRP (mg/L), and the patient's global assessment of disease activity and physician's global assessment of disease activity; SDAI scores range from 0 to 86, where lower scores indicate less disease activity. A score of ≤3.3 was considered to be SDAI remission. Participants with missing data were considered to have failed to achieve the outcome.

Time frame: Month 12

Percentage of Participants With American College or Rheumatology (ACR)20, ACR50, and ACR70 at Month 12

ACR20/50/70 response was calculated as improvement (from baseline) of at least 20/50/70% (respectively) of tender and of swollen joints, and improvement from baseline of least 20/50/70% (respectively) in at least 3 of the 5 following parameters: participant's pain assessment, patient's global assessment of disease activity, physician's global assessment of disease activity, health assessment questionnaire disability index (HAQ-DI) score, and ESR (mm/hour) or CRP (mg/L). Participants with missing data were considered to have failed to achieve the outcome.

Time frame: Month 12

Percentage of Participants With Good or Moderate European League Against Rheumatism (EULAR) Response at Month 12

EULAR response was categorized as good or moderate response and was calculated as the difference between DAS28-ESR scores at baseline and Month 12. DAS28-ESR was calculated from the number of swollen joints and tender joints using the 28-joint count, ESR (mm/hour) and patient's global assessment of disease activity; scores range from 0 to 10, where lower scores indicate less disease activity. * If diminution from baseline \>1.2 and score ≤3.2 at Month 12 = good response * If diminution from baseline \>1.2 and score \>3.2 at Month 12 = moderate response * If diminution from baseline \>0.6 and ≤1.2, and score ≤5.1 at Month 12 = moderate response * If diminution from baseline \>0.6 and ≤1.2, and score \>5.1 at Month 12 = non-response * If diminution from baseline ≤1.2 at Month 12 = non-response * Participants with missing data were considered as non-response

Time frame: Month 12

Mean Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) Score

The HAQ-DI is a participant-reported assessment of ability to perform daily living activities. This composite index score ranges from 0 (normal) to 3 (total functional disability) and includes questions regarding 8 domains (dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week). A decrease in score corresponds to improvement in participant-assessed health state.

Time frame: Baseline; Month 6; Month 12

Mean Change From Baseline in Rheumatoid Arthritis Impact of Disease (RAID) Score

The RAID questionnaire is a participant-reported outcome measure evaluating the impact of rheumatoid arthritis on participant quality of life. This composite index score ranges from 0 (best) to 10 (worst) and includes questions regarding 7 domains (pain, functional disability assessment, fatigue, sleep, physical well-being, emotional well-being, coping). A decrease in score corresponds to improvement in participant-assessed health state.

Time frame: Baseline; Month 6, Month 12

Percentage of Participants With Acceptable Health State Assessed by the Patient Acceptable Symptom State (PASS) Questionnaire.

Participants were asked: "If you were to remain in the same condition for the next few months as you have been over the last 8 days, would this be 1) acceptable, 2) unacceptable?" The percentage of participants who responded "acceptable" at each time point is presented.

Time frame: Baseline; Month 6; Month 12

Percentage of Participants With Adverse Events

An adverse event was defined as any unfavorable and unintended sign (including an abnormal laboratory finding if accompanied by clinical symptoms, results in a change in study treatment, results in a medical intervention or a change in concomitant therapy or clinically significant in the investigator's judgment), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

Time frame: Up to 30 months